Recombinant human soluble thrombomodulin (rhTM) is a novel class of anticoagulants for treating disseminated intravascular coagulation (DIC). Although rhTM is widely used in clinical settings throughout Japan, there is limited clinical evidence supporting the use of rhTM in patients with sepsis-induced DIC. Furthermore, rhTM is not approved for DIC treatment in other countries. This study aimed to clarify the survival benefits of rhTM administration in critically ill patients. Data from 3,195 consecutive adult patients who were admitted to 42 intensive care units for the treatment of severe sepsis or septic shock between January 2011 and December 2013 were retrospectively analysed, and 1,784 patients were diagnosed with DIC based on the scoring algorithm from the Japanese Association for Acute Medicine DIC (n = 645, rhTM group; n = 1,139, control group). Propensity score matching created 452 matched pairs, and logistic regression analysis revealed a significant association between rhTM administration and lower in-hospital all-cause mortality in the propensity score-matched groups (odds ratio, 0.757; 95% CI, 0.574-0.999, P = 0.049). Inverse probability of treatment weighted and quintile-stratified analyses also revealed significant associations between rhTM administration and lower in-hospital all-cause mortality. Survival time in the propensity score-matched rhTM group was significantly longer than that in the propensity score-matched control group (hazard ratio, 0.781; 95% CI, 0.624-0.977, P = 0.03). Bleeding complications were not more frequent in the rhTM groups. In conclusion, this study demonstrated that rhTM administration is associated with reduced in-hospital all-cause mortality among patients with sepsis-induced DIC.
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Introduction Thrombomodulin (TM) is a receptor of thrombin and protein C on the endothelial cell surface and regulates the coagulation and complement system (1) . Recombinant human soluble thrombomodulin (rhTM) is a novel class of anticoagulants for the treatment of disseminated intravascular coagulation (DIC). The molecular structure of rhTM consists of the active and extracellular domains of TM on the endothelial cell surface (2) . Similar to the function of TM on the endothelial cell surface, rhTM can bind to thrombin and activate protein C (2) . In Japan, rhTM (Asahi Kasei Pharma Co., Tokyo, Japan) was approved in 2008 and is widely used for DIC treatment in various clinical settings (2) (3) (4) . Furthermore, the DIC treatment guidelines from the International and Japanese Society of Thrombosis and Hemostasis recommend the use of rhTM in patients with sepsis-induced DIC (4-6).
However, there is very limited clinical evidence supporting the use of rhTM in patients with sepsis-induced DIC. In a double-blind, randomized, controlled, phase 3 study of Japanese patients with DIC-associated sepsis and haematological malignancy, the improvement in DIC and bleeding symptoms was significantly greater with rhTM treatment than with heparin treatment (2) . Furthermore, a retrospective sub-analysis of 80 patients with sepsis-induced DIC in the same study indicated a trend towards better outcomes in the rhTM group, compared to those in the heparin group (7) . In the clinical setting, the results of a retrospective observational study indicated that rhTM reduced in-hospital mortality among patients with sepsis-induced DIC (8, 9). However, results from an analysis of a nationwide administrative database indicated no benefit for rhTM administration in patients with sepsis-induced DIC (10, 11). The major limitation of these studies was the lack of laboratory data and clinical severity in the database (10, 11). However, a randomized, controlled, phase 2b study that was conducted in Europe suggested that rhTM was effective among patients with sepsis-associated coagulopathy and severe organ dysfunction (12) . Furthermore, in a meta-analysis, rhTM was associated with a trend towards reduced mortality among patients with sepsis-induced DIC (13) . Although a phase 3
trial is currently recruiting participants to clarify the effects of rhTM (14) , there is limited clinical evidence supporting the use of rhTM in patients with sepsis-induced DIC. Therefore, we conducted the present multicentre retrospective observational study to analyse the effect of rhTM treatment on sepsis-induced DIC using propensity score analysis.
Materials and Methods
This retrospective observational study (Japan Septic Disseminated Intravascular Coagulation [JSEPTIC DIC] study) was conducted in 42 intensive care units (ICUs) from 40 institutions throughout Japan (Supplemental Tables 1 and 2 ) and was approved by the Institutional Review Board of each hospital. The boards waived the requirement for informed consent, due to the retrospective design.
Patient selection and data collection
We retrospectively reviewed information for consecutive patients who were admitted to the ICUs for the treatment of severe sepsis or septic shock between January 2011 and December 2013. Severe sepsis and septic shock were defined based on the International Sepsis Definitions Conference criteria (15) . We excluded patients who were <16 years old, or patients who developed severe sepsis or septic shock after their ICU admission.
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including anti-DIC drugs, other anticoagulants, immunoglobulins, and low-dose steroids, during the first week after ICU admission; transfusion amounts and bleeding complications during the first week after ICU admission; therapeutic interventions, including surgical interventions at the infection site, renal replacement therapy, renal replacement therapy for non-renal indications, polymyxin B direct hemoperfusion, extracorporeal membrane oxygenation, and intra-aortic balloon pumping, during the first week after ICU admission; and outcomes in the hospital.
The DIC score was calculated using the scoring algorithm from the Japanese Association for Acute Medicine (JAAM) DIC criteria (19) . Missing values were scored as zero. Patients with DIC were defined as patients without a pre-existing haemostatic disorder and with a single-day DIC score of ≥4 during the first week after ICU admission (on day 1, 3, or 7). Patients were divided into the following two groups: the rhTM group (received rhTM) and the control group (did not receive rhTM). Among the patients with DIC, rhTM was used at the discretion of the attending physician, and there was no predefined protocol regarding rhTM administration. Typically, 380 U/kg·day was intravenously administered to patients with DIC and without severe renal dysfunction. Among patients with DIC and severe renal dysfunction, the dosage of rhTM was maintained at 130 U/kg·day. rhTM administration was usually continued for 6 days or until improvement of the DIC.
score of each organ (except coagulation) on day 1; SIRS score on day 1; DIC score on day 1; primary infection site; blood culture results; microorganisms responsible for the sepsis; laboratory tests (white blood cell count, platelet count, haemoglobin level, and prothrombin time-international normalized ratio) on day 1; anti-DIC drugs; other anticoagulants; immunoglobulins; low-dose steroids; surgical interventions at the infection site; renal replacement therapy; renal replacement therapy for non-renal indications; polymyxin B direct hemoperfusion; extracorporeal membrane oxygenation; intra-aortic balloon pumping; ICU characteristics; ICU policy; and number of beds in the ICU. Some laboratory tests (fibrinogen, fibrin/fibrinogen degradation products, D-dimer, antithrombin, and lactate) were not used to estimate the propensity score because the proportion of missing data was >10%. In the present analysis, we used the therapeutic interventions to estimate the propensity score because they were usually performed simultaneously with rhTM administration. The calliper width was 0.15 of the standard deviation of the logit of the propensity score. The standardised difference was used to evaluate covariate balance, and an absolute standardised difference of >10% represents meaningful imbalance (20) .
For the propensity score matched patients, we performed logistic regression analysis fitted with generalized estimating equations to examine the association between rhTM administration and in-hospital all-cause mortality, after accounting for the matched nature of matched pairs (21) . To evaluate the robustness of the results of the propensity score matching analysis, inverse probability of treatment weighted analysis and quintile-stratified propensity score analysis were performed. Cox regression analysis with a sandwich variance estimator (22) was used to assess differences in the in-hospital survival rates between the propensity score-matched rhTM and control groups. In the logistic regression analysis fitted with generalized estimating equations, inverse probability of treatment weighted analysis and Cox regression analysis, we used rhTM administration alone as an independent variable. In the quintile-stratified propensity score analysis, we used rhTM and propensity score strata as independent variables. Intergroup comparisons were performed using the Wilcoxon signed-rank test or McNemar's test
in the propensity score-matched groups.
R software (version 3.1.3) with the "MATCHIT" package was used for the propensity score estimation and matching (23, 24) , and SAS ® software (version 9.4; SAS Institute Inc., Cary, NC, USA)
was used for all other analyses.
Results
The JSEPTIC study included 3,195 consecutive patients with severe sepsis or septic shock, and 1,784 of these patients were diagnosed with DIC (n = 645, rhTM group; n = 1,139, control group).
Propensity score matching created 452 matched pairs ( Figure 1 ). The characteristics of the ICUs, according to the unmatched and propensity score-matched groups, are presented in Table 1 , while the characteristics of the patients in the unmatched and propensity score-matched groups are shown in Table 2 . Although some patients were missing specific results from the laboratory tests at the ICU admission, the other variables were typically available. The clinical severity and intensity of the therapeutic interventions were imbalanced between the unmatched groups. No patients received recombinant human activated protein C, because it was not approved in Japan during the study period.
After propensity score matching, all of the standardised differences, except those for fibrinogen and lactate, were <10% in the matched patients, and the characteristics of the two groups were appropriately balanced.
The odds ratios for in-hospital all-cause mortality with rhTM administration are presented in Figure 2 . In all of the propensity score analyses (propensity score matching, inverse probability of treatment weighted, and quintile-stratified analyses), significant associations were observed between rhTM administration and lower in-hospital all-cause mortality. The 28-day mortality rates and odds ratios according to the three propensity score analyses are presented in Table 3 . The 28-day mortality rates in 9 / 26 rhTM group were consistently lower than those in the control group, although 453 patients (25.4%) among the 1,784 patients with DIC were not followed for all 28 days, as they were discharged within 28 days after their ICU admission. Survival time analysis revealed a significant difference in the in-hospital survival between the propensity score-matched groups (hazard ratio, 0.781; 95% confidence interval, 0.624-0.977, P = 0.03) (Figure 3 ). The transfusion amounts and frequencies of bleeding complications
were not significantly different between the propensity score-matched groups (Table 4) .
Discussion
The present multicentre retrospective study used propensity score analysis of clinical information, and the findings indicate that rhTM improved in-hospital all-cause mortality among patients with sepsis-induced DIC, without increasing the frequency of bleeding complications. Furthermore, half of the patients simultaneously received rhTM and other anti-DIC drugs. Therefore, the present results indicate the additional benefits of rhTM when it is coadministered with other anti-DIC drugs, especially antithrombin.
In Japan, rhTM and other anti-DIC drugs are approved and widely used for DIC treatment in various clinical settings. However, some physicians do not administer anti-DIC drugs to patients with DIC because the Surviving Sepsis campaign guidelines do not provide recommendations for the treatment of DIC (25, 26) . Therefore, some of the patients with sepsis-induced DIC in the present study did not receive any anti-DIC drugs; as a result, we were able to retrospectively compare the effects of rhTM among patients with sepsis-induced DIC in real clinical settings.
A previous randomized, controlled, phase 2b study that was conducted in Europe did not report survival benefits after rhTM treatment among patients with modified International Society of Thrombosis and Hemostasis (ISTH) overt-DIC, although benefits were observed among patients with sepsis-associated coagulopathy and severe organ dysfunction (12) . However, based on the JAAM DIC criteria (19) , the present results suggest that rhTM provides a survival benefit for patients with DIC.
Nevertheless, the characteristics of patients with DIC vary according to whether they are diagnosed using the JAAM DIC criteria or ISTH overt-DIC criteria (19, 27) , as patients with greater clinical severity are selected using the JAAM DIC scoring system (27) . This difference is reflected in the different mortality rates among the control groups from the present study and the phase 2b European study: 25.5% and 21.6%, respectively (12) . Furthermore, rhTM administration might only improve mortality among patients with sepsis-induced DIC who have a high risk of death, but not among patients who have a low risk of death (28) .
Similar to TM, rhTM binds to thrombin and activates protein C on endothelial cells (2, 29) .
Activated protein C degrades activated factors V and VIII in the presence of protein S, which results in the attenuation of thrombin generation (30, 31) . Therefore, rhTM has two types of anticoagulant action:
direct inhibition of thrombin and indirect activation of protein C (29) . However, in the clinical setting, the plasma concentration of rhTM does not reach the level that is required to directly inhibit thrombin, as the rhTM concentration that is required for this action is 50× higher than that to activate protein C (2, 29, 32).
Therefore, in the clinical setting, the main anticoagulation effects of rhTM are achieved by activating protein C (2, 29, 32). Furthermore, unlike recombinant human-activated protein C, the anti-coagulant effects of rhTM are dependent on thrombin activity in the systemic circulation, as rhTM cannot activate protein C after the attenuation of thrombin generation (2, 29) . In addition to its anticoagulant activities, the anti-inflammatory effects of rhTM include the inhibition of leukocyte adhesion to endothelial cells, inhibition of complement pathways, neutralization of lipopolysaccharides, suppression of inflammatory cytokines, and degradation of high-mobility group box 1 protein (33, 34). Thus, rhTM administration could be considered appropriate treatment for patients with sepsis-induced DIC.
Bleeding complications are the greatest concern that is associated with the use of anticoagulants, such as rhTM. In the present study, the transfusion amounts and frequencies of bleeding
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requiring transfusion were not higher in the matched rhTM group, despite the co-administration of other anti-DIC drugs. Similarly, previous studies have reported that rhTM, which was administered independent of other anti-DIC drugs, did not increase the frequency of bleeding complications among patients with sepsis (9, 12).
The present study has several limitations that warrant consideration. First, we could not identify the exact timing of the therapeutic interventions. However, the therapeutic interventions and administration of rhTM were usually performed simultaneously at the ICU admission, and the therapeutic interventions were not affected by rhTM administration. Therefore, we considered it acceptable to use the therapeutic interventions to estimate the propensity score. Second, the dose and duration of rhTM administration were not known. However, we assumed that the patients received 380 U/kg of rhTM (or 180 U/kg in patients with severe renal dysfunction) during the first 6 days or until improvement of their DIC. Third, the data set was missing some data, although these missing data were only regarding specific laboratory test results (fibrinogen, fibrin/fibrinogen degradation products, D-dimers, antithrombin, and lactate) at the ICU admission. Fourth, we used a retrospective design, which is more likely to report beneficial effects for an intervention, and this phenomenon has been observed for various drugs, such as activated protein C (Xigris ® , Eli Lilly) (35) .
Conclusions
Based on propensity score analysis of clinical data, the present multicentre retrospective study revealed that rhTM administration was associated with reduced in-hospital all-cause mortality among patients with sepsis-induced DIC. Furthermore, the transfusion amounts and frequencies of bleeding requiring transfusion did not increase in the rhTM group. Nevertheless, multicentre randomized trials using an appropriate DIC scoring system are needed to determine the true benefits of rhTM.
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Figure legends In all of the propensity score analyses, significant associations were observed between rhTM administration and lower in-hospital all-cause mortality.
Odds ratios (black squares) and 95% confidence intervals (bars)
IPTW, inverse probability of treatment weighted; rhTM, recombinant human soluble thrombomodulin
Figure 3 Survival plots for patients in the propensity score-matched control and rhTM groups
The survival rate was higher in the rhTM group, compared to that in the control group.
rhTM, recombinant human soluble thrombomodulin Data are presented as n (%), mean ± standard deviation, or median (interquartile range). Data are presented as n (%) or odds ratio (95% confidence interval) 452  294  177  113  64  46  452  274  157  97  62  39 rhTM Control Figure 3 
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